随着 nemolizumab 在 FDA 的批准，期待其在全球范围内的上市能够给更多患者带来希望。Galderma 还正在积极与其他多个国家的监管机构合作，期盼这款重磅药物能更广泛地服务于全球患者。根据统计，目前在美国，约有 181,000 名患者正受到 prurigo nodularis 的困扰，而这款新药的上市，无疑为他们打开了一扇希望之窗。...
“这些结果为 nemolizumab 销售披上了光鲜的外衣,展示了它能够为 prurigo nodularis 患者带来的巨大潜力。”——Baldo Scassellati Sforzolini,Galderma 全球研发负责人 “这一发现显示了 nemolizumab 背后科学的强大与创新,可能成为改善患者生活质量的新希望!”——Sonja Ständer教授,德国明斯特大学医院的皮肤科研...
原始出处: Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks in Extension Study.https://www.medscape.com/viewarticle/prurigo-nodularis-nemolizumab-efficacy-persists-52-weeks-2024a10004w4?form=fpf
Nemolizumab’s approval is based on positive results from the phase 3 OLYMPIA clinical trials, which is the largest clinical trial program conducted for prurigo nodularis to date. In the trial, nemolizumab demonstrated significant and clinically meaningful improvements in itch and skin nodules at ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25thWorld Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizumab monotherapy in patients with prurigo nodularis, with signi...
Zug, Switzerland – July 4, 2023 –Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25thWorld Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizumab monotherapy in patients with prurigo nodula...
Results from the phase III OLYMPIA 1 trial in patients with prurigo nodularis also met both primary endpoints and all key secondary endpoints, confirming nemolizumab’s rapid onset of action on itch.2 81% of adults with atopic dermatitis describe itch as among their three most problematic sympto...
PRURIGOATOPYADULTSIntroduction It is unknown whether baseline demographics and disease characteristics have an influence on efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis (PN). Objectives To report safety and efficacy of nemolizumab in th...
IL-31 signaling is known to drive pruritus and is associated with changes in epidermal differentiation, inflammation, and fibrosis among individuals who suffer from prurigo nodularis. The FDA’s approval of the drug follows the positive results from the phase 3 OLYMPIA clinical trial designed to ...
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis Background: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. ....